GLP-1 Receptor Agonists and Gastrointestinal Effects

Mechanism of Action and Effects on the GI Tract

The American College of Gastroenterology notes that GLP-1 receptor agonists affect gastrointestinal function through delayed gastric emptying, reduced gastric acid secretion, and increased gastric volumes, primarily impacting the upper GI tract 1, 2
The European Society of Gastrointestinal Motility states that GLP-1 receptor agonists have no direct mechanism for fat malabsorption, which is the typical cause of floating stools (steatorrhea) 1, 2

The American Gastroenterological Association reports that GLP-1 receptor agonists can cause delayed gastric emptying with retained gastric contents, documented in 24.2-56% of patients despite prolonged fasting 3
The American College of Clinical Pharmacy notes that constipation is a significant risk with semaglutide, demonstrating a risk ratio of 6.17 4

The National Institute of Diabetes and Digestive and Kidney Diseases recommends assessing for concurrent medications or conditions affecting fat absorption in patients on GLP-1 therapy with persistent floating stools 4
The American College of Gastroenterology suggests evaluating dietary fat intake, as excessive fat consumption can cause floating stools independent of medication effects 4
The European Society of Gastrointestinal Motility states that GI adverse effects are dose-dependent and occur more frequently with short-acting formulations than long-acting preparations 4
The American Gastroenterological Association notes that most GI adverse events occur within the first month of therapy and may improve with continued use due to tachyphylaxis 1, 2

The American Society of Anesthesiologists should be aware that both oral and subcutaneous semaglutide formulations carry aspiration risk under anesthesia, with extended fasting periods not eliminating this risk, and gastric ultrasound findings showing solids in the stomach after an 8-hour fast 5
The perioperative management of patients on semaglutide warrants similar precautions for both formulations, due to the mechanism of delayed gastric emptying, although no route-specific guidelines exist 5
Gastric emptying delay is a class effect of GLP-1 receptor agonists, mediating delayed gastric emptying as part of the therapeutic mechanism for appetite suppression and glucose control, with dose-dependent effects and potential tachyphylaxis 5

Diarrhea is a recognized side effect of GLP-1 receptor agonists during active treatment, occurring alongside nausea, vomiting, and constipation, according to the Obesity Reviews 6
Gastric emptying gradually returns to normal as the medication's effect on delaying gastric motility wears off, with a decreasing prevalence of gastric retention with each additional day of drug discontinuation, as reported in Anaesthesia 7

If a patient develops diarrhea after stopping GLP-1 therapy, it is not a recognized withdrawal effect, and alternative causes should be considered, as stated in Obesity Reviews 6

The American Society of Anesthesiologists recommends that "gassiness" in patients on GLP-1 receptor agonists should not be assumed to be benign intestinal gas, as it may represent significant gastric distension with retained contents, creating an aspiration risk if the patient requires anesthesia 8, 9
Patients with persistent severe abdominal pain require immediate evaluation for pancreatitis or gallbladder disease, and the GLP-1 agonist should be discontinued promptly if pancreatitis is suspected, with a strength of evidence based on clinical guidelines from the American College of Gastroenterology 8